Prime Medicine, Inc. Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities
Prime Medicine, Inc. (PRME) reported Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities of -$3.62 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities · last filed 2026-08-06
- Prime Medicine, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2026-06-30 was $880.00K, a 82.28% decline year-over-year.
- Prime Medicine, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2026-03-31 was -$4.50M.
- Prime Medicine, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2025-12-31 was $1.60M.
- Prime Medicine, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2025-09-30 was -$1.07M, a 118.06% decline year-over-year.
- Prime Medicine, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2025 was -$1.16M, a 162.94% decline from fiscal 2024.
- Prime Medicine, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2024 was $1.84M, a 4.84% increase from fiscal 2023.
- Prime Medicine, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2023 was $1.76M.
- Prime Medicine, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2022 was -$25.87M, a 173.49% decline from fiscal 2021.
| Period end | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 3 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 6 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 9 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $880.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$3.62M 10-Q · filed 2026-08-06 | -$2.02M derived: sum of 3 quarters · filed 2026-08-06 | -$3.09M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$4.50M 10-Q · filed 2026-05-07 | -$2.90M derived: sum of 2 quarters · filed 2026-05-07 | -$3.97M derived: sum of 3 quarters · filed 2026-05-07 | $993.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $1.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $530.00K derived: sum of 2 quarters · filed 2026-03-03 | $5.50M derived: sum of 3 quarters · filed 2026-08-06 | -$1.16M 10-K · filed 2026-03-03 |
| 2025-09-30 | -$1.07M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $3.90M derived: sum of 2 quarters · filed 2026-08-06 | -$2.76M 10-Q · filed 2025-11-07 | -$2.90M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $4.96M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$1.69M 10-Q · filed 2026-08-06 | -$1.83M derived: sum of 3 quarters · filed 2026-08-06 | $4.09M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$6.66M 10-Q · filed 2026-05-07 | -$6.80M derived: sum of 2 quarters · filed 2026-05-07 | -$873.00K derived: sum of 3 quarters · filed 2026-05-07 | -$337.00K derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$144.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $5.78M derived: sum of 2 quarters · filed 2026-03-03 | $6.32M derived: sum of 3 quarters · filed 2026-03-03 | $1.84M 10-K · filed 2026-03-03 |
| 2024-09-30 | $5.93M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $6.46M derived: sum of 2 quarters · filed 2025-11-07 | $1.99M 10-Q · filed 2025-11-07 | $4.50M derived: sum of 4 quarters · filed 2025-11-07 |
| 2024-06-30 | $536.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$3.94M 10-Q · filed 2025-08-07 | -$1.43M derived: sum of 3 quarters · filed 2025-08-07 | $1.26M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | -$4.47M 10-Q · filed 2025-05-08 | -$1.96M derived: sum of 2 quarters · filed 2025-05-08 | $721.00K derived: sum of 3 quarters · filed 2025-05-08 | $1.33M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $2.51M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $5.20M derived: sum of 2 quarters · filed 2025-02-28 | $5.80M derived: sum of 3 quarters · filed 2025-02-28 | $1.76M 10-K · filed 2025-02-28 |
| 2023-09-30 | $2.68M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $3.29M derived: sum of 2 quarters · filed 2024-11-12 | -$755.00K 10-Q · filed 2024-11-12 | $3.33M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $608.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$3.44M 10-Q · filed 2024-08-08 | $650.00K derived: sum of 3 quarters · filed 2024-08-08 | $1.54M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$4.05M 10-Q · filed 2024-05-10 | $42.00K derived: sum of 2 quarters · filed 2024-05-10 | $932.00K derived: sum of 3 quarters · filed 2024-05-10 | $3.40M derived: sum of 4 quarters · filed 2024-05-10 |
| 2022-12-31 | $4.09M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-01 | $4.98M derived: sum of 2 quarters · filed 2024-03-01 | $7.45M derived: sum of 3 quarters · filed 2024-03-01 | -$25.87M 10-K · filed 2024-03-01 |
| 2022-09-30 | $890.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | $3.36M derived: sum of 2 quarters · filed 2023-11-03 | -$29.96M 10-Q · filed 2023-11-03 | $3.35M derived: sum of 4 quarters · filed 2023-11-03 |
| 2022-06-30 | $2.47M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | -$30.85M 10-Q · filed 2023-08-07 | $2.46M derived: sum of 3 quarters · filed 2023-08-07 | |
| 2022-03-31 | -$33.32M 10-Q · filed 2023-05-11 | -$11.00K derived: sum of 2 quarters · filed 2023-05-11 | ||
| 2021-12-31 | $33.31M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $35.21M 10-K · filed 2023-03-09 | ||
| 2021-09-30 | $1.90M 10-Q · filed 2022-11-14 | |||
| 2020-12-31 | $302.00K 10-K · filed 2023-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B |